Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $13.2 million.

  • Phathom Pharmaceuticals' Prepaid Assets fell 1170.23% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year decrease of 1170.23%. This contributed to the annual value of $20.9 million for FY2024, which is 5814.76% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Prepaid Assets stood at $13.2 million for Q3 2025, which was down 1170.23% from $14.6 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Prepaid Assets ranged from a high of $20.9 million in Q4 2024 and a low of $975000.0 during Q3 2022
  • Its 4-year average for Prepaid Assets is $11.1 million, with a median of $12.9 million in 2023.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Prepaid Assets soared by 122697.44% in 2023 and then plummeted by 1170.23% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Prepaid Assets stood at $5.1 million in 2022, then surged by 157.34% to $13.2 million in 2023, then surged by 58.15% to $20.9 million in 2024, then crashed by 36.61% to $13.2 million in 2025.
  • Its last three reported values are $13.2 million in Q3 2025, $14.6 million for Q2 2025, and $13.1 million during Q1 2025.